The Session

Thursday closed with a broadly risk-off tone, the result of a macro concern that refused to stay in the background. Investors spent the session reassessing whether the Federal Reserve might raise its benchmark interest rate — the federal funds rate — before year-end, a scenario that had largely been dismissed earlier in 2026 as the market priced in a path of cuts. The shift in expectations was enough to pull equities lower across the board, even as the corporate news flow was anything but uniformly negative.

The day's losses were not driven by a single catalyst. No Fed statement landed, no economic data release triggered the repricing. Instead, the rate-hike anxiety appeared to reflect a slow accumulation of inflationary pressure signals — including a sharp warning from Goldman Sachs about Persian Gulf supply disruptions — that collectively nudged market participants toward a more defensive posture. When the macro narrative shifts without a clean trigger, it tends to be stickier than a single-event selloff.

Winners and Losers

The session's most dramatic move belonged to AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS), which reported that Wainua — their drug targeting ATTR-CM, a progressive heart condition caused by protein buildup in cardiac tissue — failed to outperform a placebo in a pivotal clinical trial. Pivotal trials are the final large-scale studies regulators require before considering a drug for approval; a failure at this stage eliminates the drug's commercial prospects entirely. AstraZeneca shed approximately $27 billion in market capitalization on the result. For Ionis, which co-developed the therapy, the outcome removes a meaningful pipeline asset at a late stage of development. Both companies will need to reassess their cardiovascular strategies.

The scale of the loss is a reminder of how much probability-weighted value pharmaceutical investors embed in late-stage assets. Markets had clearly priced in a meaningful chance of approval; that premium evaporated in a single session.

On the opposite side of the ledger, Vertex Pharmaceuticals (VRTX) moved aggressively to replenish its own pipeline, agreeing to acquire Crinetics Pharmaceuticals (CRNX) for approximately $10 billion. Crinetics, which focuses on endocrine diseases, saw its shares surge roughly 99% over the week following the announcement — a move consistent with the substantial premium Vertex is paying. The deal signals continued appetite among large-cap drugmakers for bolt-on acquisitions rather than internal development, and extends Vertex well beyond its established cystic fibrosis franchise.

In technology, the AI infrastructure buildout continued at a pace that seemed indifferent to the broader market's caution. Apple (AAPL) extended its chip supply agreement with Broadcom (AVGO) through 2031 in a deal expected to exceed $30 billion, cementing Broadcom's role as a critical supplier of custom silicon. Apollo Global Management began trading a $35 billion private credit financing package — debt arranged outside traditional bank channels — structured for Broadcom and AI startup Anthropic, aimed at expanding AI infrastructure capacity. And AMD (AMD) announced plans to deploy six gigawatts of GPU capacity for Meta, a commitment that underscores the depth of hyperscaler demand for compute that doesn't carry an NVDA label. Taken together, the three deals illustrate how AI capital spending is now flowing through chip design, manufacturing agreements, and private debt markets simultaneously.

Under the Surface

Goldman Sachs added a geopolitical layer to the session's inflationary anxiety. The bank — which had previously forecast an oil glut — issued a warning that renewed hostilities in the Persian Gulf could meaningfully disrupt global crude supplies. The reversal is notable: Goldman had been among the more bearish voices on oil prices heading into the second half of 2026. Supply disruptions in the Gulf, a critical transit corridor for seaborne crude, can tighten the global energy market quickly and feed directly into consumer price indices. That feedback loop — higher oil, stickier inflation, more pressure on the Fed — is precisely the dynamic that made the Goldman note land with weight on a day already sensitive to rate risk.

The VIX and Treasury markets will have absorbed some of this anxiety, with rate-sensitive sectors likely bearing the brunt of the equity weakness. The bond market's read on the Fed's terminal rate is the cleaner signal to track than any single equity move.

Elsewhere in markets, SpaceX joined the Nasdaq-100 index, a structural event expected to force passive index funds — vehicles that automatically hold every constituent of a benchmark in proportion to its weight — to purchase approximately $4.3 billion of shares to match the new composition. The QQQ ETF and other Nasdaq-100 tracking products will increase their aerospace and satellite exposure as a result. The mechanics of the trade are being closely watched given SpaceX's limited public float, which could amplify price moves as funds compete to acquire their required allocations.

Tomorrow's Setup

The dominant carry-forward question is whether the Fed rate-hike concern has legs or fades as quickly as it arrived. Without a specific catalyst — a hawkish Fed speaker, a hot inflation print, or a further escalation in Persian Gulf tensions — the anxiety could dissipate. But Goldman's oil supply warning introduces a variable that is harder to dismiss: if tanker traffic through the Strait of Hormuz remains constrained, energy prices will move, and the Fed's calculus becomes genuinely more complicated.

For healthcare investors, AstraZeneca and Ionis will face pressure to articulate pipeline alternatives. The Wainua failure leaves a gap in both companies' cardiovascular strategies that will not be easily filled. Watch for management commentary on next steps and whether either company signals an interest in M&A to compensate for the lost asset.

The AI deal flow — Apollo's credit package, the AMD-Meta GPU commitment, the Apple-Broadcom extension — reinforces that infrastructure spending is not slowing. But the rate environment matters for how that spending is financed. Private credit deals like Apollo's $35 billion package are priced relative to prevailing rates; a Fed that raises rather than cuts would tighten the terms on which AI infrastructure gets funded. That tension between AI's capital appetite and the macro rate backdrop is the frame worth holding into next week.